TSXV:CLAS.H - Post by User
Comment by
MyKnighton Jun 18, 2019 10:58am
![](https://assets.stockhouse.com/kentico-cms/0340-00/images/Sprite.svg#id_Post_Views_Icon)
61 Views
Post# 29835693
RE:RE:RE:Nice volume again today. Let's knock this .05 wall down
RE:RE:RE:Nice volume again today. Let's knock this .05 wall downAgree with you Looking4Doubles,
I was impress by the KAL-1816 and especially this line
specifically target the alpha3 glycine pain receptor, and is at least 40-fold more potent than desoxy-cannabidiol Looking4Doubles - (6/18/2019 10:54:41 AM) RE:RE:Nice volume again today. Let's knock this .05 wall down McKnight: I added another small amount on the news as well. This is the comment I especially liked:
" KAL-1816 is the first cannabinoid pharmaceutical designed to specifically target the alpha3 glycine pain receptor, and is at least 40-fold more potent than desoxy-cannabidiol, which is a prototypic alpha3 glycine receptor agonist. looking to free up some more cash.".
I see the wall as a win-win for me. The longer it's there, the longer I can add a lot of cheap shares. I can wait ! Just glad I found this company last fall. GLA ! ! I think we have a tiger by the tail. - Hang on for the ride